Clinical trial NCT00587795: Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace
Official title: Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Radius Fractures
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: AirCast LLC
First posted: 2008-01-07
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objectives:

- To obtain clinical evidence for the safety and efficacy in using the StabilAir Wrist Fracture Brace for the following cases:

1. Acute (emergency department) treatment of non-displaced, stable extra- articular distal radius fractures;
2. To obtain comparative data between traditional therapies (sugar tong, plaster backslab, long arm or short arm cast) and the use of the StabilAir brace for each patient qualified by specific criteria.

Hypothesis:

1) For stable, non-displaced fractures, the StabilAir Brace is as effective as a sugar tong splint in the acute setting. 2) In cases where full forearm immobilization is initially preferred, the StabilAir is effective as a follow-up to sugar tong splitting once the need for full immobilization has passed.

Detailed description: Data Collection and Study Design:

This will be a single center, prospective, randomized controlled trial. The investigators planned to collect data from 80 patients with undisplaced distal radius fractures. Half were to be treated with the plastic back slab or sugar tong splint (if there were an ulnar styloid fracture) and half were to be treated with the StabilAir splint. The initial treatment, which was to occur upon the patient's arrival at the emergency room and prior to study randomization, required full forearm and wrist immobilization in the acute phase treated with sugar tong splinting. At the patient's follow-up visit, which was to happen ≤10 days post injury and initial evaluation, when it was determined that full forearm immobilization was no longer necessary, patients were informed of the study, consented, and randomized (as in the flip of a coin) to one of the two study groups using a computerized randomization process that was controlled by the study coordinator. One study group was to consist of patients treated with either sugar tong splint or plaster casting and the other study group was to consist of patients treated with the StabilAir brace. Throughout entire study, the sugar tong splint/casting patients was to be the control group.

Patients were to be asked to return for the following visits after they were randomized:

* 10-14 days post randomization
* 35 to 42 days (5 to 6 weeks) post randomization
* 77 to 84 days (11 to 12 weeks) post randomization;
* And at 12 and 24 months.

At each visit they were to have x-rays of their wrist and an exam with the physician. In addition, they were to be asked to complete questionnaires regarding their general health, daily activities and pain.

Eligibility criteria: Inclusion Criteria:

* Males and Females Age ≥ 18 yrs
* Undisplaced distal radial fractures (with/without ulnar styloid fractures)

Exclusion Criteria:

* Age \< 18 yrs
* Intra-articular fracture - displaced
* Loss of reduction after cast or brace treatment
* Excessive comminution (\> 50% metophysis)
* Failed closed reduction (CR) (Unacceptable alignment status post CR: Short \>2mm; Dorsal angulation \>0° (neutral), Radial inclination \< 15°)
* Ipsilateral ulna fractures (not styloid)
* Open fracture
* Senile or dementia or lack of understanding of treatment
* Previous fracture distal radius
* Patients with displaced fractures that require pin fixation, external fixation, plate fixation or who qualify for "crystalline injection fracture healing protocol" are excluded from the study

Primary outcomes:
measure: Change in Distal Radius Fracture at 8 Weeks
timeFrame: baseline, 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David G Dennison, MD
role: PRINCIPAL_INVESTIGATOR
References: